A2A and A2B adenosine receptors: The extracellular loop 2 determines high (A2A) or low affinity (A2B) for adenosine

被引:23
|
作者
De Filippo, Elisabetta [1 ]
Hinz, Sonja [1 ]
Pellizzari, Veronica [2 ]
Deganutti, Giuseppe [2 ]
El-Tayeb, Ali [1 ]
Navarro, Gemma [5 ]
Franco, Rafael [3 ,4 ]
Moro, Stefano [2 ]
Schiedel, Anke C. [1 ]
Mueller, Christa E. [1 ]
机构
[1] Univ Bonn, PharmaCtr Bonn, Pharmaceut Inst, Pharmaceut & Med Chem, Immenburg 4, D-53121 Bonn, Germany
[2] Univ Padua, Dept Pharmaceut & Pharmacol Sci, MMS, Via Marzolo 5, Padua, Italy
[3] Univ Barcelona, Dept Biochem & Mol Biomed, Avda Diagonal 643, E-08028 Barcelona, Spain
[4] Ctr Nacl Salud Carlos III, Ctr Invest Red Enfermedades Neurodegenerat CiberN, Madrid, Spain
[5] Univ Barcelona, Fac Pharm & Food Sci, Dept Biochem & Physiol, Barcelona, Spain
关键词
Adenosine; cAMP; Extracellular loop; GPCR; Chimeric receptor; Radioligand binding; PROTEIN-COUPLED RECEPTORS; MOLECULAR-DYNAMICS SUMD; LIGAND RECOGNITION; SUBTYPE-SELECTIVITY; BINDING; DEAMINASE; MEMBRANES; RESIDUES; PATHWAY; A(1);
D O I
10.1016/j.bcp.2019.113718
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
A(2A) and A(2B) adenosine receptors (ARs) are closely related G protein-coupled receptor subtypes, which represent important (potential) drug targets. Despite their almost identical binding sites for adenosine, A(2A)ARs are activated by low (nanomolar) adenosine concentrations, while A(2B)ARs require micromolar concentrations. In the present study, we exchanged the extracellular loop 2 (ECL2) of the human A(2A)AR for that of the A(2B)AR. The resulting chimeric A(2A)(ECL2-A(2B))AR was investigated in radioligand binding and cAMP accumulation assays in comparison to the wildtype A(2A)AR. While the ribose-modified adenosine analog N-ethylcarboxamidoadenosine (NECA) and its 2-substituted derivative CGS-21680 did not exhibit significant changes, adenosine showed dramatically reduced potency and affinity for the A(2A)(ECL2-A(2B))AR mutant displaying similarly low potency as for the wt A(2B)AR. Supervised molecular dynamics simulation studies predicted a meta-binding site with high affinity for adenosine, but not for NECA, which may contribute to the observed effects.
引用
收藏
页数:14
相关论文
共 50 条
  • [41] Therapeutic Potential of Agonists and Antagonists of A1, A2a, A2b and A3 Adenosine Receptors
    Jamwal, Sumit
    Mittal, Ashish
    Kumar, Puneet
    Alhayani, Dana M.
    Al-Aboudi, Amal
    [J]. CURRENT PHARMACEUTICAL DESIGN, 2019, 25 (26) : 2892 - 2905
  • [42] Adenosine and osteoporosis:: Adenosine A2A and A2B receptor blockade or deletion leads to diminished bone density
    Kara, Firas M.
    Axelrod, Matthew
    Sloane, Jennifer
    Doty, Steve
    Boskey, Adele
    Cronstein, Bruce N.
    [J]. ARTHRITIS AND RHEUMATISM, 2008, 58 (09): : S648 - S649
  • [43] Both A2a and A2b adenosine receptors at reperfusion are necessary to reduce infarct size in mouse hearts
    Methner, Carmen
    Schmidt, Katharina
    Cohen, Michael V.
    Downey, James M.
    Krieg, Thomas
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2010, 299 (04): : H1262 - H1264
  • [44] Endogenous adenosine increases coronary flow by activation of both A2A and A2B receptors:: studies in isolated A2A receptor knockout hearts
    Talukder, MAH
    Morrison, RR
    Ledent, C
    Mustafa, SJ
    [J]. FASEB JOURNAL, 2002, 16 (05): : A859 - A860
  • [45] Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy
    Kalhan, A.
    Gharibi, B.
    Vazquez, M.
    Jasani, B.
    Neal, J.
    Kidd, M.
    Modlin, I. M.
    Pfragner, R.
    Rees, D. A.
    Ham, J.
    [J]. PURINERGIC SIGNALLING, 2012, 8 (02) : 265 - 274
  • [46] EFFECT OF TRAINING ON ADENOSINE A2A AND A2B RECEPTOR EXPRESSION IN HUMAN SKELETAL MUSCLE
    Lynge, J.
    Betak, A.
    Hellsten, Y.
    [J]. MEDICINE AND SCIENCE IN SPORTS AND EXERCISE, 2001, 33 (05): : S330 - S330
  • [47] Adenosine A2A and A2B receptor expression in neuroendocrine tumours: potential targets for therapy
    A. Kalhan
    B. Gharibi
    M. Vazquez
    B. Jasani
    J. Neal
    M. Kidd
    I. M. Modlin
    R. Pfragner
    D. A. Rees
    J. Ham
    [J]. Purinergic Signalling, 2012, 8 : 265 - 274
  • [48] Characterization of novel dual A2A/A2B adenosine receptor antagonists for cancer immunotherapy
    Galezowski, Michal
    Wegrzyn, Paulina
    Bobowska, Aneta
    Commandeur, Claude
    Dziedzic, Katarzyna
    Nowogrodzki, Marcin
    Obara, Alicja
    Szeremeta-Spisak, Joanna
    Dzielak, Anna
    Lozinska, Iwona
    Dudek, Marcelina
    Janiga, Anita
    Reus, Jacek
    Wronowski, Marek
    Swirski, Mateusz
    Radzimierski, Adam
    Ziembik, Magdalena
    Mierzwicka, Joanna
    Wojcik-Jaszczynska, Katarzyna
    Gocek, Elzbieta
    Grycuk, Karolina
    Golas, Aniela
    Pierzchala, Olga
    Zachmann, Julian
    Nowak, Mateusz
    [J]. CANCER RESEARCH, 2018, 78 (13)
  • [49] Facilitation of noradrenaline release by adenosine A2A receptors in the epididymal portion and adenosine A2B receptors in the prostatic portion of the rat vas deferens
    Queiroz, G
    Diniz, C
    Gonçalves, J
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 2002, 448 (01) : 45 - 50
  • [50] Human adenosine A2A and A2B receptors transfected into Chinese hamster ovary cells mediate activation of extracellular regulated kinases
    Schulte, G
    Fredholm, BB
    [J]. JOURNAL OF NEUROCHEMISTRY, 1999, 73 : S134 - S134